Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)



Status:Completed
Conditions:Breast Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/23/2019
Start Date:September 26, 2013
End Date:October 28, 2016

Use our guide to learn which trials are right for you!

A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in
combination with either gemcitabine or carboplatin to the combination of gemcitabine and
carboplatin as first line treatment in female subjects with triple negative metastatic breast
cancer (TNMBC) or metastatic triple negative breast cancer.

ABI-007-MBC- 001 is a Phase 2/3, multicenter, open-label, randomized, study that will compare
the safety and efficacy of weekly nab-paclitaxel in combination with gemcitabine or
carboplatin to the combination of gemcitabine and carboplatin as first line therapy in female
subjects with Estrogen Receptor (ER), Progesterone Receptor (PgR), and human epidermal growth
factor receptor 2 (HER2) negative (triple negative) metastatic breast cancer (TNMBC) or
metastatic triple negative breast cancer. In the phase 2 portion of the study, the
combinations of nab-paclitaxel plus gemcitabine and nab-paclitaxel plus carboplatin will be
evaluated, and a comparator arm of gemcitabine combined with carboplatin will be used. In the
phase 3 portion of the study, the selected nab-paclitaxel combination treatment will be
compared to gemcitabine combined with carboplatin to evaluate progression free survival,
safety and tolerability, overall survival, disease control rate and duration of response in
women with metastatic triple negative breast cancer.

Due to changes in the treatment landscape since the initiation of this trial, the decision
was made not to proceed to the Phase 3 portion of the study.

Inclusion Criteria: A subject will be eligible for inclusion in this study only if all of
the following criteria are met:

1. Female subjects, age ≥ 18 years at the time informed consent is signed

2. Pathologically confirmed adenocarcinoma of the breast

3. Pathologically confirmed as triple negative, source documented, defined as both of the
following

1. Estrogen Receptor (ER) and Progesterone Receptor (PgR) negative: < 1% of tumor
cell nuclei are immunoreactive in the presence of evidence that the sample can
express ER or PgR (positive intrinsic controls)

2. Human Epidermal Growth Factor Receptor 2 (HER2) negative as per American Society
of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines i.
Immunohistochemistry (IHC) 0 or 1 Fluorescence In Situ Hybridization (FISH)
negative (or equivalent negative test). Subjects with IHC 2 must have a negative
by Fluorescence In Situ Hybridization (FISH),, (or equivalent negative test).

4. Subjects with prior breast cancer history of different phenotypes (ie, ER/PgR/HER2
positive) must have pathologic confirmation of triple negative disease in at least one
of the current sites of metastasis

5. Subjects must have received prior adjuvant or neoadjuvant anthracycline therapy;
unless (a) anthracycline treatment was not indicated or was not the best treatment
option for the subject in the opinion of the treating physician; and (b) anthracycline
treatment remains not indicated or, in the opinion of the treating physician, is not
the best treatment option for the subject's metastatic disease.

a. Newly diagnosed subjects presenting with TNMBC are eligible for the study if
anthracycline treatment is not indicated or is not the best treatment option for the
subject in the opinion of the treating physician.

6. Subjects with measurable metastatic disease, defined by Response Evaluation Criteria
in Solid Tumors 1.1 (RECIST 1.1) guidelines

7. Life expectancy ≥ 16 weeks from randomization

8. No prior cytotoxic chemotherapy for metastatic breast cancer. Prior immunotherapy
and/or monoclonal antibody therapy are acceptable. Prior treatments must have been
discontinued at least 30 days prior to start of study treatment and all related
toxicities must have resolved to Grade 1 or less.

9. Prior neoadjuvant or adjuvant chemotherapy, if given, must have been completed at
least 6 months before randomization with all related toxicities resolved, and
documented evidence of disease progression per RECIST 1.1 guidelines is required.

a. If prior neoadjuvant or adjuvant chemotherapy contained taxane, gemcitabine, or
platinum agents, the treatment must have completed at least 12 months before
randomization

10. Prior radiotherapy must have completed before randomization, with full recovery from
acute radiation side effects. At least one measurable lesion must be completely
outside the radiation portal or there must be unequivocal radiologic or clinical exam
proof of progressive disease within the radiation portal, in accordance with RECIST
1.1 guidelines

11. At least 30 days from major surgery before randomization, with full recovery

12. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

13. Subject has the following blood counts at screening:

- Absolute Neutrophil Count (ANC) ≥ 1500/mm^2 ;

- Platelets ≥ 100,000/mm^2 ;

- Hemoglobin (Hgb) ≥ 9 g/dL

14. Subject has the following blood chemistry levels at screening:

- Aspartate aminotransferase (AST) Serum glutamic-oxaloacetic transaminase (SGOT),
Alanine Aminotransferase (ALT ) Serum Glutamic Pyruvate Transaminase (SGPT) ≤ 2.5
x upper limit of normal range (ULN); if hepatic metastases present ≤ 5.0 x ULN

- Total serum bilirubin ≤ ULN; or total bilirubin ≤ 3.0 × ULN with direct bilirubin
within normal range in subjects with documented Gilbert's Syndrome

- Creatinine clearance > 60 mL/min (by Cockcroft-Gault)

15. Females of child-bearing potential [defined as a sexually mature women who (1) have
not undergone hysterectomy (the surgical removal of the uterus) or bilateral
oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally
postmenopausal for at least 24 consecutive months (i.e., has had menses at any time
during the preceding 24 consecutive months)] must:

- Demonstrate a negative serum pregnancy test result at screening (performed by
central lab) confirmed by local negative urine pregnancy dipstick within 72 hours
prior to the first dose of IP); pregnancy test with sensitivity of at least 25
mIU/mL; and

- Either commit to true abstinence* from heterosexual contact (which must be
reviewed on a monthly basis) or agree to use, and be able to comply with, two
physician approved effective contraception methods (oral, injectable, or
implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier
contraceptive with spermicide; or vasectomized partner) without interruption for
28 days or longer as required by local guidelines, prior to starting study drug,
during the study therapy (including dose interruptions), and for 28 days after
discontinuation of the study or longer as required by local guidelines

16. Females must abstain from breastfeeding starting at randomization, during study
participation and for 28 days or longer as required by local guidelines, after IP
discontinuation

17. Understand and voluntarily sign an informed consent document prior to any study
related assessments/procedures are conducted

18. Able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria
apply:

1. Male subjects

2. Concurrent chemotherapy or any other anti tumor therapy for breast cancer. Prior
immunotherapy & monoclonal antibody therapy are acceptable.

3. Subjects who received prior cytotoxic chemotherapy after incomplete resection of
locoregional recurrent disease

4. History of, or known current evidence of brain metastasis, including leptomeningeal
involvement.

5. Subjects with bone as the only site of metastatic disease

6. Subjects with regional lymph node as the only site of metastatic disease

7. Serious intercurrent medical or psychiatric illness, including serious active
infection

8. History of class II-IV congestive heart failure or myocardial infarction within 6
months of randomization

9. History of other primary malignancy in the last 5 years prior to randomization.
Subjects with prior breast cancer history are eligible, however, the most recently
obtained biopsy must demonstrate triple negative disease (source documented). Subjects
with prior history of in situ cancer or basal or localized squamous cell skin cancer
are eligible.

10. Subjects with a history of interstitial lung disease, history of slowly progressive
dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis,
pulmonary hypersensitivity pneumonitis or multiple uncontrolled or unstable allergies
which, in the opinion of the investigator, may lead to serious complications

11. Peripheral neuropathy Grade ≥ 2 by National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI CTCAE) v4.0

12. Subjects who have received an investigational product within the previous 4 weeks
prior to randomization

13. Subject is currently enrolled, or will enroll in a different clinical study in which
investigational therapeutic procedures are performed or investigational therapies are
administered while participating in this study

14. Pregnant or nursing women

15. Subjects with prior hypersensitivity to nab-paclitaxel, gemcitabine, carboplatin or
any other platin, or nucleoside analogue agents

16. Any significant medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from participating in the study

17. Any condition including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if she were to participate in the study

18. Any condition that confounds the ability to interpret data from the study

19. History of seropositive human immunodeficiency virus (HIV)

20. Subjects who are receiving immunosuppressive or myelosuppressive medications that
would, in the opinion of the investigator, increase the risk of serious neutropenic
complications
We found this trial at
64
sites
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Boca Raton, Florida 33486
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
166 Stoneridge Drive
Columbia, South Carolina 29210
803-461-3000
South Carolina Oncology Associates, PA South Carolina Oncology Associates (SCOA) is the only comprehensive cancer...
?
mi
from
Columbia, SC
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
220 S Palisade Dr # 204
Santa Maria, California 93454
?
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Anaheim, California 92801
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Baltimore, Maryland 21201
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
6410 Rockledge Dr #660
Bethesda, Maryland 20817
(301) 571-0019
Center for Cancer & Blood Disorders Widely recognized for its compassionate, expert care, the Center...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Burlington, North Carolina 27215
?
mi
from
Burlington, NC
Click here to add this to my saved trials
Chandler, Arizona 85224
?
mi
from
Chandler, AZ
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Cincinnati, Ohio 45219
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
5053 Wooster Rd
Cincinnati, Ohio 45226
(513) 751-2273
Oncology Hematology Care Our more than 60 physicians and advanced practice providers throughout neighborhood offices...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
3100 Plaza Properties Blvd
Columbus, Ohio 43219
(614) 383-6000
The Mark H. Zangmeister Center At The Zangmeister Center, we appreciate that our patients have...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Coos Bay, Oregon 97420
?
mi
from
Coos Bay, OR
Click here to add this to my saved trials
Dallas, Texas 75246
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Dallas, Texas
?
mi
from
Dallas, TX
Click here to add this to my saved trials
East Syracuse, New York 13057
?
mi
from
East Syracuse, NY
Click here to add this to my saved trials
350 Engle St
Englewood, New Jersey 07631
(201) 894-3000
Englewood Hospital and Medical Center Englewood Hospital was incorporated in 1888 as a non-profit, non-sectarian...
?
mi
from
Englewood, NJ
Click here to add this to my saved trials
?
mi
from
Escondido, CA
Click here to add this to my saved trials
Fayetteville, Arkansas 72703
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
?
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Glendale, Arizona 85306
?
mi
from
Glendale, AZ
Click here to add this to my saved trials
835 S Van Buren St
Green Bay, Wisconsin 54301
(920) 433-0111
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
Hollywood, Florida
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
Hooksett, New Hampshire 03106
?
mi
from
Hooksett, NH
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Huntington, West Virginia 25701
?
mi
from
Huntington, WV
Click here to add this to my saved trials
Indianapolis, Indiana 46254
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Jacksonville, Florida 32216
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
?
mi
from
Joliet, IL
Click here to add this to my saved trials
Kansas City, Missouri 64132
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
La Verne, California 91750
?
mi
from
La Verne, CA
Click here to add this to my saved trials
?
mi
from
Lafayette, LA
Click here to add this to my saved trials
Lake Success, New York 11042
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
Langhorne, Pennsylvania 19047
?
mi
from
Langhorne, PA
Click here to add this to my saved trials
Lawton, Oklahoma 73505
?
mi
from
Lawton, OK
Click here to add this to my saved trials
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Los Angeles, California 90045
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
Milwaukee, Wisconsin 53211
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Minneapolis, Minnesota 55405
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
230 25th Ave N
Nashville, Tennessee 37203
(615) 329-7274
Sarah Cannon Cancer Center People who live with cancer
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
Portsmouth, Virginia 23704
?
mi
from
Portsmouth, VA
Click here to add this to my saved trials
Richmond, Virginia 23235
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
3015 North Ballas Road
Saint Louis, Missouri 63131
(314) 996-5000
Missouri Baptist Medical Center You just feel it. The smile that greets you. The hand...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Petersburg, Florida 33705
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Luis Obispo, California 93401
?
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
Santa Rosa, California 95403
?
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Sarasota, Florida 34232
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Scottsdale, Arizona
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
13400 E. Shea Blvd.
Scottsdale, Arizona 85259
480-301-8000
Mayo Clinic Arizona Mayo Clinic in Arizona provides medical care for thousands of people from...
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Spokane, Washington 99208
?
mi
from
Spokane, WA
Click here to add this to my saved trials
?
mi
from
Toledo, OH
Click here to add this to my saved trials
Tyler, Texas 75702
?
mi
from
Tyler, TX
Click here to add this to my saved trials
602 W University Ave
Urbana, Illinois 61801
(217) 383-3010
Carle Cancer Center Carle Cancer Center delivers comprehensive care through leading-edge technology and advanced research,...
?
mi
from
Urbana, IL
Click here to add this to my saved trials
West Palm Beach, Florida 33401
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials